제네릭 항암제 시장 규모, 점유율, 동향 및 성장 분석 보고서(2026-2034년)

The Generic Oncology Drugs Market size is expected to reach USD 61.03 Billion in 2034 from USD 35.46 Billion (2025) growing at a CAGR of 6.22% during 2026-2034.

The Global Generic Oncology Drugs Market is expanding rapidly as the demand for cost-effective cancer treatments continues to rise worldwide. Generic oncology drugs provide affordable alternatives to branded cancer medications, making life-saving treatments accessible to a larger patient population. The increasing global burden of cancer and rising healthcare costs are major factors driving the adoption of generic oncology therapies.

Patent expirations of several major cancer drugs have opened opportunities for generic drug manufacturers to introduce more affordable treatment options. These medications maintain similar safety and efficacy profiles as branded drugs while significantly reducing treatment expenses. Governments and healthcare providers are encouraging the use of generics to improve accessibility and reduce healthcare expenditure.

In the future, the Global Generic Oncology Drugs Market is expected to grow as more cancer drugs lose patent protection and generic alternatives become available. Pharmaceutical companies are investing in large-scale production and regulatory approvals to expand their presence in the oncology sector. With the increasing demand for affordable cancer therapies and expanding healthcare coverage, the market is projected to experience strong long-term growth.

Our reports are meticulously crafted to provide clients with comprehensive and actionable insights into various industries and markets. Each report encompasses several critical components to ensure a thorough understanding of the market landscape:

Market Overview: A detailed introduction to the market, including definitions, classifications, and an overview of the industry's current state.

Market Dynamics: In-depth analysis of key drivers, restraints, opportunities, and challenges influencing market growth. This section examines factors such as technological advancements, regulatory changes, and emerging trends.

Segmentation Analysis: Breakdown of the market into distinct segments based on criteria like product type, application, end-user, and geography. This analysis highlights the performance and potential of each segment.

Competitive Landscape: Comprehensive assessment of major market players, including their market share, product portfolio, strategic initiatives, and financial performance. This section provides insights into the competitive dynamics and key strategies adopted by leading companies.

Market Forecast: Projections of market size and growth trends over a specified period, based on historical data and current market conditions. This includes quantitative analyses and graphical representations to illustrate future market trajectories.

Regional Analysis: Evaluation of market performance across different geographical regions, identifying key markets and regional trends. This helps in understanding regional market dynamics and opportunities.

Emerging Trends and Opportunities: Identification of current and emerging market trends, technological innovations, and potential areas for investment. This section offers insights into future market developments and growth prospects.

MARKET SEGMENTATION

By Drug Type

• Chemotherapy drugs
• Targeted therapy drugs
• Immunotherapy drugs
• Hormonal therapy drugs
• Other drug types

By Indication

• Prostate cancer
• Lung cancer
• Breast cancer
• Colorectal cancer
• Leukemia
• Other indications

By Route of Administration

• Oral
• Topical
• Injectable

By Distribution Channel

• Hospital pharmacies
• Retail pharmacies
• Online pharmacies

COMPANIES PROFILED

• AbbVie Inc, Apotex Inc, AstraZeneca, Biocon Ltd, Gland Pharma Limited Incyte Corporation, Lupin Pharmaceuticals Inc, Mylan NV, Natco Pharma Ltd, Novartis Pharmaceuticals Corporation, Pfizer Inc, Regeneron Pharmaceuticals Inc, Synthon Pharmaceuticals Inc, Teva Pharmaceuticals, Zydus Lifesciences Limited
• We can customise the report as per your requirements.

TABLE OF CONTENTS

Chapter 1. PREFACE

• 1.1. Market Segmentation & Scope
• 1.2. Market Definition
• 1.3. Information Procurement
  • 1.3.1 Information Analysis
  • 1.3.2 Market Formulation & Data Visualization
  • 1.3.3 Data Validation & Publishing
• 1.4. Research Scope and Assumptions
  • 1.4.1 List of Data Sources

Chapter 2. EXECUTIVE SUMMARY

• 2.1. Market Snapshot
• 2.2. Segmental Outlook
• 2.3. Competitive Outlook

Chapter 3. MARKET VARIABLES, TRENDS, FRAMEWORK

• 3.1. Market Lineage Outlook
• 3.2. Penetration & Growth Prospect Mapping
• 3.3. Value Chain Analysis
• 3.4. Regulatory Framework
  • 3.4.1 Standards & Compliance
  • 3.4.2 Regulatory Impact Analysis
• 3.5. Market Dynamics
  • 3.5.1 Market Drivers
  • 3.5.2 Market Restraints
  • 3.5.3 Market Opportunities
  • 3.5.4 Market Challenges
• 3.6. Porter's Five Forces Analysis
• 3.7. PESTLE Analysis

Chapter 4. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY DRUG TYPE 2022-2034 (USD MN)

• 4.1. Market Analysis, Insights and Forecast Drug Type
• 4.2. Chemotherapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.3. Targeted therapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.4. Immunotherapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.5. Hormonal therapy drugs Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 4.6. Other drug types Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 5. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY INDICATION 2022-2034 (USD MN)

• 5.1. Market Analysis, Insights and Forecast Indication
• 5.2. Prostate cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.3. Lung cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.4. Breast cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.5. Colorectal cancer Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.6. Leukemia Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 5.7. Other indications Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 6. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY ROUTE OF ADMINISTRATION 2022-2034 (USD MN)

• 6.1. Market Analysis, Insights and Forecast Route Of Administration
• 6.2. Oral Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.3. Topical Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 6.4. Injectable Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 7. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY DISTRIBUTION CHANNEL 2022-2034 (USD MN)

• 7.1. Market Analysis, Insights and Forecast Distribution Channel
• 7.2. Hospital pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.3. Retail pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)
• 7.4. Online pharmacies Estimates and Forecasts By Regions 2022-2034 (USD MN)

Chapter 8. GLOBAL GENERIC ONCOLOGY DRUGS MARKET: BY REGION 2022-2034(USD MN)

• 8.1. Regional Outlook
• 8.2. North America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.2.1 By Drug Type
  • 8.2.2 By Indication
  • 8.2.3 By Route Of Administration
  • 8.2.4 By Distribution Channel
  • 8.2.5 United States
  • 8.2.6 Canada
  • 8.2.7 Mexico
• 8.3. Europe Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.3.1 By Drug Type
  • 8.3.2 By Indication
  • 8.3.3 By Route Of Administration
  • 8.3.4 By Distribution Channel
  • 8.3.5 United Kingdom
  • 8.3.6 France
  • 8.3.7 Germany
  • 8.3.8 Italy
  • 8.3.9 Russia
  • 8.3.10 Rest Of Europe
• 8.4. Asia-Pacific Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.4.1 By Drug Type
  • 8.4.2 By Indication
  • 8.4.3 By Route Of Administration
  • 8.4.4 By Distribution Channel
  • 8.4.5 India
  • 8.4.6 Japan
  • 8.4.7 South Korea
  • 8.4.8 Australia
  • 8.4.9 South East Asia
  • 8.4.10 Rest Of Asia Pacific
• 8.5. Latin America Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.5.1 By Drug Type
  • 8.5.2 By Indication
  • 8.5.3 By Route Of Administration
  • 8.5.4 By Distribution Channel
  • 8.5.5 Brazil
  • 8.5.6 Argentina
  • 8.5.7 Peru
  • 8.5.8 Chile
  • 8.5.9 South East Asia
  • 8.5.10 Rest of Latin America
• 8.6. Middle East & Africa Market Analysis, Insights and Forecast, 2022-2034 (USD MN)
  • 8.6.1 By Drug Type
  • 8.6.2 By Indication
  • 8.6.3 By Route Of Administration
  • 8.6.4 By Distribution Channel
  • 8.6.5 Saudi Arabia
  • 8.6.6 UAE
  • 8.6.7 Israel
  • 8.6.8 South Africa
  • 8.6.9 Rest of the Middle East And Africa

Chapter 9. COMPETITIVE LANDSCAPE

• 9.1. Recent Developments
• 9.2. Company Categorization
• 9.3. Supply Chain & Channel Partners (based on availability)
• 9.4. Market Share & Positioning Analysis (based on availability)
• 9.5. Vendor Landscape (based on availability)
• 9.6. Strategy Mapping

Chapter 10. COMPANY PROFILES OF GLOBAL GENERIC ONCOLOGY DRUGS INDUSTRY

• 10.1. Top Companies Market Share Analysis
• 10.2. Company Profiles
  • 10.2.1 AbbVie Inc
  • 10.2.2 Apotex Inc
  • 10.2.3 AstraZeneca
  • 10.2.4 Biocon Ltd
  • 10.2.5 Gland Pharma Limited Incyte Corporation
  • 10.2.6 Lupin Pharmaceuticals Inc
  • 10.2.7 Mylan N.V
  • 10.2.8 Natco Pharma Ltd
  • 10.2.9 Novartis Pharmaceuticals Corporation
  • 10.2.10 Pfizer Inc
  • 10.2.11 Regeneron Pharmaceuticals Inc
  • 10.2.12 Synthon Pharmaceuticals Inc
  • 10.2.13 Teva Pharmaceuticals
  • 10.2.14 Zydus Lifesciences Limited